Study of MOMA-341 for Advanced Solid Tumors
This study is testing a new oral medication called MOMA-341 for people with advanced or metastatic (spread to other parts of the body) solid tumors. These tumors must have specific changes called MSI-H (microsatellite instability-high) or dMMR (DNA mismatch repair deficiency). MOMA-341 works by targeting a protein called Werner helicase. You might receive MOMA-341 alone, or in combination with chemotherapy (irinotecan) or immunotherapy. The main goal is to see how safe MOMA-341 is and what side effects it might cause. Researchers will also look at how your body handles the drug and if it shows any signs of helping to treat the cancer. This study plans to include up to 132 participants.
- Study design
- This is a Phase 1, open-label study, meaning you and your doctors will know which treatment you are receiving. It involves increasing doses of MOMA-341 to find the best and safest amount.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored from screening until you stop treatment, which could be up to 35 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
At a glance
Conditions
Where it's being run
15 sites across 13 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), and/or AEs leading to discontinuationFrom screening until treatment discontinuation (up to 35 months)
To assess the safety and tolerability of MOMA-341 given as a single-agent, and in combination with irinotecan, and in combination with immunotherapy